Bionovo, Inc. (NASDAQ: BNVI) announced today that it will host a conference call on Tuesday, August 30, 2011, to discuss the results of the completed Tolerability Trial of its drug candidate for menopausal hot flashes, Menerba, at 2:00 p.m. Pacific Time. It will also discuss its overall clinical development plan and the impending Phase 3 [...]

Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), today announced 20.7 month median overall survival (OS) from a prior single-arm Phase 2 trial evaluating bavituximab in combination with docetaxel in patients with locally advanced or metastatic breast cancer. Immunomedics, Inc. (Nasdaq:IMMU) gave a pipeline update today saying that it intends to initiate a Phase 3 trial in 2012 [...]

Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), today announced 20.7 month median overall survival (OS) from a prior single-arm Phase 2 trial evaluating bavituximab in combination with docetaxel in patients with locally advanced or metastatic breast cancer. Immunomedics, Inc. (Nasdaq:IMMU) gave a pipeline update today saying that it intends to initiate a Phase 3 trial in 2012 [...]

 VIVUS, Inc. (NASDAQ: VVUS), today announced that it has entered into definitive agreements sell 6,889,098 shares of its common stock in a registered direct offering at $6.65 per share, resulting in gross proceeds of approximately $45.8 million. Seattle Genetics, Inc. (NASDAQ:SGEN) today announced that it has initiated a phase 2 clinical trial of ADCETRIS(TM) (brentuximab [...]

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that its ridaforolimus partner, Merck, has submitted a marketing authorization application (MAA) for ridaforolimus with the European Medicines Agency (EMA). The submission occurred on July 29, 2011. Amarin Corporation plc (Nasdaq:AMRN) announced today the successful completion of all remaining studies required for its NDA for AMR101 for the [...]

Insmed Incorporated (Nasdaq: INSM), announced the FDA has placed a clinical hold on its Phase 3 clinical trials for ARIKACE in Cystic Fibrosis (CF) patients with Pseudomonas lung infections and patients with non-tuberculous mycobacterial (NTM) lung disease. It has been informed by the FDA that this decision was based on an initial review of the [...]

If companies are unable to push their bid price above $1 they either face delisting from NASDAQ to OTCBB or will require a reverse split to remain on NASDAQ. Most of the companies below face no meaningful upcoming catalysts to propel their bid price above $1. Which companies are in this category? I have 7 [...]

AspenBio Pharma, Inc. (NASDAQ: APPY), effected today a one for five reverse split of its common shares to ensure continued compliance with NASDAQ minimum bid price rule listing requirements. However it only reduced the number of authorized common shares from 60 million to 30 million. ISTA Pharmaceuticals, Inc. (NASDAQ: ISTA) announced top-line results from the [...]

On February 14, 2011, I listed about a dozen companies facing delist from NASDAQ or a reverse split to remain listed on NASDAQ during 1H 2011. I now follow up the list by firstly noting my prediction, then what actually happened. (First bracket indicates price as of FEBRUARY 14) – (Second bracket indicates price REVERSE SPLIT [...]